Timing of the Infusion of Nivolumab for Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Esophagus Influences Its Efficacy

Overview

Journal Esophagus

Publisher Springer

Specialties Gastroenterology
Oncology

Date 2023 Apr 24

PMID 37093536

Authors

Motoo Nomura

Taisuke Hosokai

Masashi Tamaoki

Akira Yokoyama

Shigemi Matsumoto

Manabu Muto

Affiliations

Soon will be listed here.

Abstract

Background: The immune system is affected by the circadian rhythm. The objective of this study was to clarify whether time-of-day patterns (early or late in the daytime) of the infusion of nivolumab and whether its duration affect treatment efficacy in metastatic or recurrent esophageal squamous cell carcinoma (R/M-ESCC).

Methods: The data of 62 consecutive patients with R/M-ESCC treated with nivolumab between February 2017 and May 2022 were retrospectively reviewed. The infusion of nivolumab before 13:00 was set as 'early in the day', and that after 13:00 was set as 'late in the day'. The treatment efficacy was compared between early and late groups by 3 criteria (first infusion, during the first 3 months, and all treatment courses).

Results: The overall survival, progression-free survival, and response rate of patients received the first dose in the early group were significantly superior to those of patients in the late group. The progression-free survival and response rate of patients who received the majority of nivolumab infusions before 13:00 during the first 3 months were significantly superior to those who received it after 13:00, with the exception of overall survival. There were no significant differences in the overall survival, progression-free survival, and response rate between patients who received the majority of nivolumab infusions before 13:00 of all treatment courses and those who received it after 13:00.

Conclusion: The timing of the infusion of nivolumab may affect treatment efficacy in R/M-ESCC.

Citing Articles

Avelumab Maintenance Therapy in Advanced Urothelial Carcinoma: Implications of Timing and Treatment Sequencing.

Goncalves L, Guedes H, Fortuna A, Lemos T, Gramaca J, Mourao N Cancers (Basel). 2025; 17(5).

PMID: 40075745 PMC: 11898965. DOI: 10.3390/cancers17050898.

Personalization of Cancer Treatment: Exploring the Role of Chronotherapy in Immune Checkpoint Inhibitor Efficacy.

Fey R, Billo A, Clister T, Doan K, Berry E, Tibbitts D Cancers (Basel). 2025; 17(5).

PMID: 40075580 PMC: 11899640. DOI: 10.3390/cancers17050732.

Chrono-immunotherapy as a low-hanging fruit for cancer treatment? A call for pragmatic randomized clinical trials.

Ozdemir B, Bill R, Okyar A, Scheiermann C, Hayoz S, Olivier T J Immunother Cancer. 2025; 13(3).

PMID: 40032603 PMC: 11877229. DOI: 10.1136/jitc-2024-010644.

Outcomes of Avelumab Treatment in Advanced Urothelial Carcinoma According to Age, Performance Status, and Timing.

Furubayashi N, Mochida M, Kijima A, Fujimoto Y, Nakamura M, Negishi T In Vivo. 2025; 39(2):976-987.

PMID: 40010984 PMC: 11884485. DOI: 10.21873/invivo.13903.

Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study.

Huang Z, Karaboue A, Zeng L, Lecoeuvre A, Zhang L, Li X EBioMedicine. 2025; 113:105607.

PMID: 39983330 PMC: 11893323. DOI: 10.1016/j.ebiom.2025.105607.

References

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Watanabe M, Tachimori Y, Oyama T, Toh Y, Matsubara H, Ueno M . Comprehensive registry of esophageal cancer in Japan, 2013. Esophagus. 2020; 18(1):1-24. PMC: 7794110. DOI: 10.1007/s10388-020-00785-y. View

Sun J, Shen L, Shah M, Enzinger P, Adenis A, Doi T . Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021; 398(10302):759-771. DOI: 10.1016/S0140-6736(21)01234-4. View

Doki Y, Ajani J, Kato K, Xu J, Wyrwicz L, Motoyama S . Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med. 2022; 386(5):449-462. DOI: 10.1056/NEJMoa2111380. View

Kato K, Cho B, Takahashi M, Okada M, Lin C, Chin K . Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20(11):1506-1517. DOI: 10.1016/S1470-2045(19)30626-6. View

Kojima T, Shah M, Muro K, Francois E, Adenis A, Hsu C . Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin Oncol. 2020; 38(35):4138-4148. DOI: 10.1200/JCO.20.01888. View

Hrushesky W . Circadian timing of cancer chemotherapy. Science. 1985; 228(4695):73-5. DOI: 10.1126/science.3883493. View

Qian D, Kleber T, Brammer B, Xu K, Switchenko J, Janopaul-Naylor J . Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncol. 2021; 22(12):1777-1786. DOI: 10.1016/S1470-2045(21)00546-5. View

Karaboue A, Collon T, Pavese I, Bodiguel V, Cucherousset J, Zakine E . Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer. Cancers (Basel). 2022; 14(4). PMC: 8870559. DOI: 10.3390/cancers14040896. View

10.

Phillips A, Gallagher S, Carroll D, Drayson M . Preliminary evidence that morning vaccination is associated with an enhanced antibody response in men. Psychophysiology. 2008; 45(4):663-6. DOI: 10.1111/j.1469-8986.2008.00662.x. View

11.

Long J, Drayson M, Taylor A, Toellner K, Lord J, Phillips A . Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial. Vaccine. 2016; 34(24):2679-85. PMC: 4874947. DOI: 10.1016/j.vaccine.2016.04.032. View

12.

de Bree L, Mourits V, Koeken V, Moorlag S, Janssen R, Folkman L . Circadian rhythm influences induction of trained immunity by BCG vaccination. J Clin Invest. 2020; 130(10):5603-5617. PMC: 7641012. DOI: 10.1172/JCI133934. View

13.

Zhang H, Liu Y, Liu D, Zeng Q, Li L, Zhou Q . Time of day influences immune response to an inactivated vaccine against SARS-CoV-2. Cell Res. 2021; 31(11):1215-1217. PMC: 8326654. DOI: 10.1038/s41422-021-00541-6. View

14.

Suzuki K, Hayano Y, Nakai A, Furuta F, Noda M . Adrenergic control of the adaptive immune response by diurnal lymphocyte recirculation through lymph nodes. J Exp Med. 2016; 213(12):2567-2574. PMC: 5110024. DOI: 10.1084/jem.20160723. View

15.

Druzd D, Matveeva O, Ince L, Harrison U, He W, Schmal C . Lymphocyte Circadian Clocks Control Lymph Node Trafficking and Adaptive Immune Responses. Immunity. 2017; 46(1):120-132. PMC: 5263259. DOI: 10.1016/j.immuni.2016.12.011. View

16.

Wang S, Meyer D, Schumacher B . Inheritance of paternal DNA damage by histone-mediated repair restriction. Nature. 2022; 613(7943):365-374. PMC: 9834056. DOI: 10.1038/s41586-022-05544-w. View

17.

Tsuruta A, Shiiba Y, Matsunaga N, Fujimoto M, Yoshida Y, Koyanagi S . Diurnal Expression of PD-1 on Tumor-Associated Macrophages Underlies the Dosing Time-Dependent Antitumor Effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 Melanoma-Bearing Mice. Mol Cancer Res. 2022; 20(6):972-982. PMC: 9381128. DOI: 10.1158/1541-7786.MCR-21-0786. View

18.

Brahmer J, Drake C, Wollner I, Powderly J, Picus J, Sharfman W . Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28(19):3167-75. PMC: 4834717. DOI: 10.1200/JCO.2009.26.7609. View

19.

Bellesoeur A, Ollier E, Allard M, Hirsch L, Boudou-Rouquette P, Arrondeau J . Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?. Cancers (Basel). 2019; 11(11). PMC: 6895963. DOI: 10.3390/cancers11111784. View

20.

Fransen M, van Hall T, Ossendorp F . Immune Checkpoint Therapy: Tumor Draining Lymph Nodes in the Spotlights. Int J Mol Sci. 2021; 22(17). PMC: 8431673. DOI: 10.3390/ijms22179401. View